Dual antiretroviral regimen maintains durable HIV suppression after switch
Treatment-as-prevention study sees substantial levels of transmitted drug resistance in participants, but no impact on treatment
Integrase inhibitor bictegravir matches dolutegravir for first-line HIV treatment
